1214910-81-2

Basic information

• Product Name: C₂HF₃O₂*C₆H₁₂F₂N₂
• Synonyms: C₂HF₃O₂*C₆H₁₂F₂N₂
• CAS NO: 1214910-81-2
• Molecular Weight: 264.195
• Mol File: 1214910-81-2.mol

Chemical Properties

• CAS DataBase Reference: C₂HF₃O₂*C₆H₁₂F₂N₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂HF₃O₂*C₆H₁₂F₂N₂(1214910-81-2)
• EPA Substance Registry System: C₂HF₃O₂*C₆H₁₂F₂N₂(1214910-81-2)

Safety Data

• Hazardous Substances Data: 1214910-81-2(Hazardous Substances Data)

Upstream product

• 1214910-72-1 N'-(4,4-difluorocyclohexyl)hydrazinecarboxylic acid tert-butyl ester 
• 76-05-1 trifluoroacetic acid 
• 22515-18-0 4,4-difluorocyclohexanone 

Downstream Products

• 1082745-53-6 5-amino-1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-carbonitrile 
• 1082745-54-7 5-amino-1-(4,4-difluoro-cyclohexyl)-1H-pyrazole-4-carboxylic acid amide 
• 1214911-72-4 C₁₈H₁₉F₂N₅O₄ 
• 1214911-74-6 C₁₈H₁₇F₂N₅O₃ 
• 1214908-07-2 C₁₇H₁₇F₂N₅O 
• 1214909-62-2 C₂₅H₃₁F₂N₅O₂ 
• 1214910-10-7 C₁₈H₁₉F₂N₅O₂ 
• 1214910-24-3 C₁₈H₁₉F₂N₅O*ClH 
• 1214910-26-5 C₂₀H₁₉F₂N₇O 

Relevant articles and documents

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS

The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein ā is selected from the group A1 consisting of a C3-C8-cycloalkyl group or a C4-C8-cycloalkenyl group, whereby the members of C3-C8-cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C4-C8-cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER

The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.